» Articles » PMID: 9466566

Activation of Coagulation and Angiogenesis in Cancer: Immunohistochemical Localization in Situ of Clotting Proteins and Vascular Endothelial Growth Factor in Human Cancer

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1998 Feb 18
PMID 9466566
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Thrombin-catalyzed, cross-linked fibrin (XLF) formation is a characteristic histopathological finding in many human and experimental tumors and is thought to be of importance in the local host defense response. Although the pathogenesis of tumor-associated fibrin deposition is not entirely clear, several tumor procoagulants have been described as likely primary stimuli for the generation of thrombin (and XLF) in the tumor microenvironment (TME). In a previous study of a variety of human tumors we have shown that tissue factor (TF) is the major procoagulant. However, the relative contribution to fibrin deposition in the TME of tumor cell TF and host cell TF (eg, macrophage-derived) was not established. In addition, recent evidence has implicated TF in the regulation of the synthesis of the pro-angiogenic factor vascular endothelial growth factor (VEGF) by tumor cells. In the current study we used in situ techniques to determine the cellular localization of XLF, TF, VEGF, and an alternative tumor procoagulant, so-called cancer procoagulant (CP), a cysteine protease that activates clotting factor X. In lung cancer we have found XLF localized predominantly to the surface of tumor-associated macrophages, as well as to some endothelial cells and perivascular fibroblasts in the stromal area of the tumors co-distributed with TF at the interface of the tumor and host cells. Cancer pro-coagulant was localized to tumor cells in several cases but not in conjunction with the deposition of XLF. TF and VEGF were co-localized in both lung cancer and breast cancer cells by in situ hybridization and immunohistochemical staining. Furthermore, a strong relationship was found between the synthesis of TF and VEGF levels in human breast cancer cell lines (r2 = 0.84; P < 0.0001). Taken together, these data are consistent with a highly complex interaction between tumor cells, macrophages, and endothelial cells in the TME leading to fibrin formation and tumor angiogenesis.

Citing Articles

Tissue factor pathway inhibitor-2 (TFPI-2)-an underappreciated partaker in cancer and metastasis.

Wojtukiewicz M, Mysliwiec M, Tokajuk A, Kruszewska J, Politynska B, Jamroze A Cancer Metastasis Rev. 2024; 43(4):1185-1204.

PMID: 39153052 PMC: 11554837. DOI: 10.1007/s10555-024-10205-7.


Predictors of early colorectal cancer metastasis to lymph nodes: providing rationale for therapy decisions.

Song X, Li J, Zhu J, Kong Y, Zhou Y, Wang Z Front Oncol. 2024; 14:1371599.

PMID: 39035744 PMC: 11257837. DOI: 10.3389/fonc.2024.1371599.


Enhancing the anticancer potential of metformin: fabrication of efficient nanospanlastics, cytotoxic studies on HEP-2 cells and reactome enhanced pathway analysis.

Raafat S, Abd El Wahed S, Badawi N, Saber M, Abdollah M Int J Pharm X. 2023; 6:100215.

PMID: 38024451 PMC: 10630776. DOI: 10.1016/j.ijpx.2023.100215.


The Crossroads of the Coagulation System and the Immune System: Interactions and Connections.

Wilhelm G, Mertowska P, Mertowski S, Przysucha A, Struzyna J, Grywalska E Int J Mol Sci. 2023; 24(16).

PMID: 37628744 PMC: 10454528. DOI: 10.3390/ijms241612563.


Effects of the interactions between platelets with other cells in tumor growth and progression.

Li Y, Wang H, Zhao Z, Yang Y, Meng Z, Qin L Front Immunol. 2023; 14:1165989.

PMID: 37153586 PMC: 10158495. DOI: 10.3389/fimmu.2023.1165989.


References
1.
Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe M . A monoclonal antibody with ability to distinguish between NH2-terminal fragments derived from fibrinogen and fibrin. Mol Immunol. 1983; 20(11):1191-200. DOI: 10.1016/0161-5890(83)90142-6. View

2.
Edwards R, Morgan D, Rickles F . Animal tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost. 1990; 63(1):133-8. View

3.
Hancock W, Gee D, de Moerloose P, Rickles F, Ewan V, Atkins R . Immunohistological analysis of serial biopsies taken during human renal allograft rejection. Changing profile of infiltrating cells and activation of the coagulation system. Transplantation. 1985; 39(4):430-8. DOI: 10.1097/00007890-198504000-00018. View

4.
VanDeWater L, Tracy P, Aronson D, Mann K, Dvorak H . Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res. 1985; 45(11 Pt 1):5521-5. View

5.
Gregory S, Edgington T . Tissue factor induction in human monocytes. Two distinct mechanisms displayed by different alloantigen-responsive T cell clones. J Clin Invest. 1985; 76(6):2440-5. PMC: 424406. DOI: 10.1172/JCI112260. View